Bluecrux & Pharmaceutical Innovator Forge Path Toward QC & Supply Chain Integration: "Revolutionizing Lab Operations for Enhanced Efficiency"
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: PR Newswire
ORLANDO, Fla., April 18, 2024 /PRNewswire/ -- Bluecrux partnered with global biopharmaceutical leader AstraZeneca to drastically improve lab operations by implementing Binocs, Bluecrux's state of the art lab planning technology, across 17 of AstraZeneca's global quality control laboratories. This strategic collaboration tackles the industry-wide challenge of seamlessly integrating quality control (QC) into supply chain (SC) operations to enhance operational efficiency and responsiveness. Bluecrux and AstraZeneca will delve into the fruits of their productive partnership on stage at the Gartner Supply Chain Symposium/Xpo in Orlando, Florida, May 6 to 8.Like many biopharmaceutical companies, AstraZeneca saw a significant opportunity for integration between quality control and their supply chain. When quality control labs—critical in ensuring the safety and efficacy of pharmaceutical products—operate in isolation from the supply chain, a longer response time is required to meet fluctuati
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.MarketBeat
- CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma [Yahoo! Finance]Yahoo! Finance
- CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple MyelomaBusiness Wire
- Legend Biotech Co. (NASDAQ: LEGN) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $65.00 price target on the stock.MarketBeat
- Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.MarketBeat
LEGN
Sec Filings
- 4/22/24 - Form 6-K
- 4/16/24 - Form 6-K
- 4/8/24 - Form 6-K
- LEGN's page on the SEC website